Azitra (NYSEAMERICAN:AZTR – Get Free Report) announced its quarterly earnings data on Wednesday. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.05), FiscalAI reports.
Azitra Stock Performance
AZTR stock remained flat at $0.14 during trading on Thursday. The company had a trading volume of 452,751 shares, compared to its average volume of 9,958,622. Azitra has a fifty-two week low of $0.10 and a fifty-two week high of $1.40. The business’s fifty day simple moving average is $0.16 and its 200 day simple moving average is $0.20.
Azitra Company Profile
Azitra Inc is a clinical-stage biopharmaceutical company focused on developing live bacterial therapies for dermatological conditions. Headquartered in Cambridge, Massachusetts, the company leverages its proprietary ActoBiotic platform to formulate topical treatments that aim to modulate the skin’s native microbial ecosystem.
The company’s lead investigational therapies are being evaluated in early-phase clinical studies for inflammatory skin disorders, including atopic dermatitis and other conditions characterized by microbial imbalance.
Recommended Stories
- Five stocks we like better than Azitra
- Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
- Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal
- Lumentum Just Delivered the AI Growth Investors Wanted
- Ryman Checks Into a $1.38B Hospitality Upgrade
Receive News & Ratings for Azitra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azitra and related companies with MarketBeat.com's FREE daily email newsletter.
